If dilution, it will be after the NDA filing. If the price goes up to above $4, it is a pretty good deal.
The cash is that low, apparently they have a plan for funding. Partnership announcement soon. Buy.
The target was $5 and reached one time after the first approval. The new target was raised to above $8 after the removal of phase III requirement by FDA, and has not reached yet.
It's understandable that share price drops after the earning announcement. It will come back once people realize there is a plan for financing.
Agree. I think the management has a plan for financing when the cash reaches that low level. Either a co-development with cash incoming, or a loan from the management themselves as they did before, or great news that they can do ATM, is possible. Otherwise, the cash should not reach that low before refiancing.
Hopefully, they sold some shares the past two days and now the balance is sufficient for the next quarters. The sold ATM shares at pretty good price in the past, around $3.5 per share.
My view is that they will have a distribution partner
Wrong. The new share holders have already earned money. They have shorted the stock at around 8-10 cents before the reverse splitting before buying new shares.
That's what I am wondering too. It seems somebody knows something as shown below:
“If not the Rexista NDA filing, we believe the next catalyst is when partner Par launches the 5mg strength, as the 5mg Focalin XR dose represented a branded value of about $73 million for Novartis (NVS, Not Rated) in its annual 2014 sales, and it was about 10% of all Focalin XR sales,” the Brean Capital report noted.